This is an aggregated industry headline. Read the full story at FiercePharma →
With FDA approval for its breast cancer blockbuster hopeful, Celcuity could 'belong in the hands' of a Big Pharma
The FDA has approved a new small molecule inhibitor from Celcuity with blockbuster potential that could become a new standard-of-care for patients with breast cancer.
By FiercePharma
· Jul 15, 2026
· via FiercePharma
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlineFiercePharma
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFierceBiotech ↗
Attovia Therapeutics has filed for an IPO to secure funding for assets including a potential challenger to San…
The WeekSTAT News ↗
Blumenthal, Hawley press UnitedHealth, Humana, CVS for documents related to using AI to deny or delay care.…
The WeekBioPharma Dive ↗
Terms of the deal announced Tuesday are very similar to those the FTC reached with Express Scripts earlier thi…